BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study

Lancet

Volumn 359, Issue 9305, 2002, Pages 487-491

  Von Bubnoff, Nikolas ^a   Schneller, Folker ^a   Peschel, Christian ^a   Duyster, Justus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ARTICLE; BINDING SITE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; ENZYME ACTIVATION; GENE MUTATION; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOID TISSUE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

EID: 0037045583     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07679-1     Document Type: Article

References (17)

1. A minute chromosome in human granulocytic leukaemia
2. The biology of chronic myeloid leukaemia
3. Chronic myeloid leukaemia
4. Induction of chronic myelogenous leukaemia in mice by the P210 BCR/ABL gene of the Philadelphia chromosome
5. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products
6. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia
7. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome
8. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
9. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
10. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
11. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
12. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
13. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
14. Roots of clinical resistance to STI-571 cancer therapy
15. Roots of clinical resistance to STI-571 cancer therapy
16. Roots of clinical resistance to STI-571 cancer therapy